Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prasugrel Advisory Committee Highlights FDA’s Continued Credibility Gap

Executive Summary

Controversy over a left-out member of the advisory committee for Lilly/Daiichi Sankyo's platelet inhibitor prasugrel illustrates the challenges that FDA continues to experience in ensuring the credibility of high-profile drug reviews

You may also be interested in...



FDA’s Cardio-Renal AdComm Losing Some Of Its Anticoagulant Experience

Mori Krantz and Sanjay Kaul are rotating off the committee after participating in all three reviews of J&J/Bayer’s Factor Xa inhibitor rivaroxaban, and nearly all of the meetings on novel anti-clotting agents.

FDA Intellectual Bias Policy Takes Wolfe Off Contraceptives Safety Review

FDA offered Public Citizen’s Sidney Wolfe a seat at the table for discussion, but no vote. Members need to report relevant information about their conflicts in a timely manner, the agency says.

J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance

The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel